(Q37712230)

22 August 2017

Update on the therapy of Behçet disease (English)

1 reference

22 August 2017

0 references

Thurayya Arayssi

2

0 references

author name string

Zeinab Saleh

series ordinal

1

1 reference

22 August 2017

1 May 2014

1 reference

Therapeutic advances in chronic disease

22 August 2017

1 reference

22 August 2017

5

1 reference

22 August 2017

3

1 reference

22 August 2017

112-134

1 reference

Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

A putative functional variant within the UBAC2 gene is associated with increased risk of Behçet's disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Clinical experience with adalimumab in the treatment of ocular Behçet disease.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Clinical Immunology Review Series: an approach to the patient with recurrent orogenital ulceration, including Behçet's syndrome

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Clinical pharmacogenomics of thiopurine S-methyltransferase

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Treatment of retinal vasculitis in Behçet's disease with rituximab

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

EULAR recommendations for the management of Behçet disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Adalimumab for sight-threatening uveitis in Behçet's disease.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Behçet's disease in Lebanon: clinical profile, severity and two-decade comparison

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

A double-blind trial of depot corticosteroids in Behçet's syndrome

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Anti-TNF-alpha therapy for sight threatening uveitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

The use of interferon alpha in Behçet disease: review of the literature

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

New insights into the pathogenesis and therapy of Behçet's disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study

23 August 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

23 August 2017

https://api.crossref.org/works/10.1177%2F2040622314523062

The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Behçet's disease: a new target for anti-tumour necrosis factor treatment

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

A double-blind trial of colchicine in Behçet's syndrome

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Pharmacotherapy for Behcet's syndrome

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Pulmonary arterial aneurysms in Behçet's syndrome: a report of 24 cases.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

The efficacy of cyclosporin-a in the treatment of Behçet's disease.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Short term cyclosporin A treatment of Behçet's disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

A controlled trial of azathioprine in Behçet's syndrome

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Adalimumab for the treatment of Behçet's disease: experience in 19 patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Combination therapy with infliximab and methotrexate in recalcitrant mucocutaneous Behçet disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Resolution of Behçet's syndrome associated pulmonary arterial aneurysms with infliximab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Cerebral venous thrombosis in Behçet's disease: a systematic review.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Infliximab in refractory uveitis due to Behçet's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Treatment of colitis in Behçet's disease with thalidomide.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Interferon alfa-2a in the treatment of Behçet's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Effect of infliximab in progressive neuro-Behçet's syndrome

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behçet disease

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Azathioprine in Behcet's syndrome: effects on long-term prognosis

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Effectiveness of cyclosporin therapy for Behçet's disease

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Treatment with acyclovir does not affect orogenital ulcers in Behçet's syndrome: a randomized double-blind trial.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Treatment of Behçet disease with indomethacin

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Cyclosporine effects on optic nerve and retinal vasculitis in Behçet's disease

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Preclinical and clinical study of FK506 in uveitis

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Successful treatment with infliximab for Behçet disease during pregnancy.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Two-stage association study in Chinese Han identifies two independent associations in CCR1/CCR3 locus as candidate for Behçet's disease susceptibility.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Major vessel thrombosis in Behçet's disease: the dilemma of anticoagulant therapy - the approach of rheumatologists from different countries.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Azathioprine in severe uveitis of Behçet's disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Interferon-α treatment for acute myelitis and intestinal involvement in severe Behçet's disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Successful use of infliximab in a patient with neuro-Behçet's disease.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case report

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Resistant Behçet disease responsive to anakinra

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Interferon-alpha--a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications--results of a retrospective analysis of 117 cases.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Pulmonary artery aneurysms in Behçet syndrome

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

The treatment of recurrent uveitis with TNF-alpha inhibitors

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Treatment of recurrent perforating intestinal ulcers with thalidomide in Behçet's disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Effect of infliximab on refractory uveitis in Behcet's disease.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Efficacy of corticosteroids and cyclosporin in the treatment of retinal vasculitis in patients with Behçet's disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Effects of interferon alpha treatment on the clinical course of refractory Behçet's disease: an open study

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Long-term therapy with low dose cyclosporin A in ocular Behçet's disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Interferon-alpha 2a treatment of neuro-Behcet disease.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Ciclosporin microemulsion preconcentrate treatment of patients with Behçet's disease.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Cyclosporin-A therapy in severe uveitis of Behçet's disease.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Cyclosporin A in the treatment of severe Behçet's uveitis.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Cytokines and Behcet's disease

2 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease

2 October 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622314523062

Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622314523062

Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622314523062

Cerebral venous thrombosis in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622314523062

Successful use of canakinumab in a patient with resistant Behçet's disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992825

Cyclosporin A is effective, but not safe, in the management of Behçet's disease

3 December 2018

1 reference

12 December 2020

Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study

1 reference

12 December 2020

Low dose cyclosporin-A therapy in Behçet's disease

1 reference

12 December 2020

Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy

1 reference

12 December 2020

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

1 reference

12 December 2020

[Behçet's disease - Infliximab in the treatment of mucocutaneous manifestations]

1 reference

12 December 2020

Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease

1 reference

12 December 2020

The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease. A randomized clinical trial

1 reference

12 December 2020

One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs

1 reference

12 December 2020

Treatment of Behçet's disease with thalidomide

1 reference

12 December 2020

Thalidomide in the treatment of Behçet's syndrome

1 reference

12 December 2020

The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease

1 reference

12 December 2020

Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis

1 reference

12 December 2020

FK506 treatment of noninfectious uveitis

1 reference

12 December 2020

Epileptic seizures as the sole manifestation of neuro-Behçet's disease: complete control under interferon-alpha treatment

1 reference

12 December 2020

Results of interferon alpha-2a therapy in patients with Behcet's disease

1 reference

12 December 2020

Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease

1 reference

12 December 2020

Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation

1 reference

12 December 2020

Long-term effects of interferon alpha 2A treatment in Behçet's disease

1 reference

12 December 2020

Efficacy of infliximab on the acute attack of uveitis

1 reference

12 December 2020

Good response to infliximab in a patient with deep vein thrombosis associated with Behçet disease

1 reference

12 December 2020

Infliximab treatment for severe orogenital ulceration in Behçet's disease

1 reference

12 December 2020

Topical granulocyte colony-stimulating factor for the treatment of oral and genital ulcers of patients with Behçet's disease

1 reference

12 December 2020

Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis

1 reference

12 December 2020

Transverse myelitis in a patient with Behcet's disease: favorable outcome with a combination of interferon-alpha

1 reference

12 December 2020

Genetics of Behçet disease inside and outside the MHC

1 reference

12 December 2020

Interferon therapy for Behçet's disease

1 reference

12 December 2020

Cyclosporin A treatment of Behçet's disease: a long-term study

1 reference

12 December 2020

Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217)

1 reference

12 December 2020

Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects

1 reference

12 December 2020

Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease

1 reference

12 December 2020

A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis

1 reference

12 December 2020

Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab

1 reference

12 December 2020

Refractory neuro-Behçet treated by tocilizumab: a case report

1 reference

12 December 2020

Visual prognosis in patients with Behçet's disease receiving colchicine, systemic corticosteroid or cyclosporin

1 reference

12 December 2020

Colchicine in Behçet's disease

1 reference

12 December 2020

Long-term infliximab treatment for Behçet's disease

1 reference

12 December 2020

Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab

1 reference

12 December 2020

Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients

1 reference

12 December 2020

Low dose MTX for progressive neuro-Behçet's disease. A follow-up study for 4 years

1 reference

12 December 2020

A double blind study of colchicine in Behçet's disease

1 reference

12 December 2020

Successful treatment of long-standing neuro-Behçet's disease with infliximab

1 reference

12 December 2020

Infliximab treatment of severe genital ulcers associated with Behçet disease

1 reference

12 December 2020

Behçet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis

1 reference

12 December 2020

Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study

1 reference

12 December 2020

Efficacy of etanercept in the treatment of a patient with Behçet's disease

1 reference

12 December 2020

Interferon-alpha treatment of Behçet's disease

1 reference

12 December 2020

Long-term efficacy and safety of infliximab in the treatment of Behçet's disease

1 reference

12 December 2020

Tocilizumab treatment for neuro-Behcet's disease, the first report

1 reference

12 December 2020

Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept

1 reference

12 December 2020

Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy

1 reference

12 December 2020

Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case

1 reference

12 December 2020

Cyclosporin in Behçet's disease: results in 16 patients after 24 months of therapy

1 reference

12 December 2020

Results of interferon-alfa therapy in patients with Behçet uveitis

1 reference

12 December 2020

Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: presentation of four cases

1 reference

12 December 2020

Neurological manifestations of Behçet's disease: evaluation of 40 patients treated by cyclophosphamide

1 reference

12 December 2020

Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients

1 reference

12 December 2020

Treatment of thrombophlebitis of Behçet's disease with low dose cyclosporin A

1 reference

12 December 2020

[Effectiveness of infliximab in patients with Behçet syndrome and severe uveoretinitis. Report of five cases]

1 reference

12 December 2020

Effect of infliximab on threatening panuveitis in Behçet's disease

1 reference

12 December 2020

Infliximab treatment for ocular and extraocular manifestations of Behçet's disease

1 reference

12 December 2020

[Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease]

1 reference

12 December 2020

Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease

1 reference

12 December 2020

Identifiers

DOI

10.1177/2040622314523062

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

PMCID

3992825